{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:39:03Z","timestamp":1759991943389},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1093\/annonc\/dkf281","type":"journal-article","created":{"date-parts":[[2002,11,7]],"date-time":"2002-11-07T02:18:26Z","timestamp":1036635506000},"page":"1583-1589","source":"Crossref","is-referenced-by-count":37,"title":["Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I\/II study in first-line treatment of patients with advanced colorectal cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"W.","family":"Scheithauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.V.","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sch\u00fcll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"L\u00e4ngle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/dkf281_bb0010","first-page":"589","article-title":"Where do we stand with 5-fluorouracil?","volume":"26","author":"Schmoll","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/dkf281_bb0015","first-page":"95","article-title":"New drugs in colorectal cancer: a review of antitumor activity and cross-resistance patterns of topoisomerase I inhibitors, thymidilate synthetase inhibitors, and oxaliplatin","volume":"21","author":"Harstrick","year":"1998","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/dkf281_bb0020","first-page":"709","article-title":"The medical treatment of colorectal cancer: actual status and new developments","volume":"46","author":"Van Cutsem","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1093\/annonc\/dkf281_bb0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1248\/bpb.21.713","article-title":"Antitumor activities of a novel fluoropyrimidine, 4N-pentyloxycarbonyl-5-deoxa-5-fluorocytidine (capecitabine)","volume":"21","author":"Ishikawa","year":"1998","journal-title":"Biol Pharm Bull"},{"key":"10.1093\/annonc\/dkf281_bb0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients","volume":"45","author":"Sch\u00fcller","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/dkf281_bb0035","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/dkf281_bb0040","unstructured":"Twelves C, Harper P, Van Cutsem E et al. A phase III trial (SO14796) of xeloda (capecitabine) in previously untreated advanced\/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1199; 8: 263a (Abstr 1010)."},{"key":"10.1093\/annonc\/dkf281_bb0045","first-page":"647","article-title":"Oxaliplatin: a new therapeutic option in colorectal cancer","volume":"26","author":"Cvitkovic","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/dkf281_bb0050","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"De Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/dkf281_bb0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil\u2013leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Abstr 772","key":"10.1093\/annonc\/dkf281_bb0060","first-page":"19","article-title":"Phase I study of capecitabine in combination with oxaliplatin in patients with advanced or metastatic solid tumors","volume":"198a","author":"Diaz-Rubio","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 530","key":"10.1093\/annonc\/dkf281_bb0065","first-page":"20","article-title":"A phase I trial of capecitabine (CAPE) and oxaliplatin (OHP)","volume":"133a","author":"Thomas","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 546","key":"10.1093\/annonc\/dkf281_bb0070","first-page":"20","article-title":"A. Phase I\/II study of capecitabine (CAP) plus oxaliplatin (OXA) in first line and second line treatment of advanced or metastatic colorectal cancer (ACC)","volume":"137a","author":"Borner","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/dkf281_bb0075","first-page":"141a","article-title":"Oxaliplatin and capecitabine in advanced colorectal cancer: a dose-finding trial","volume":"20","author":"DeSantis","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/dkf281_bb0080","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer results of a randomized phase II study","volume":"18","author":"Van Cutsem","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/dkf281_bb0085","series-title":"Manual of Oncologic Therapeutics","first-page":"519","article-title":"Grading of toxicity","author":"MacDonald","year":"1995"},{"key":"10.1093\/annonc\/dkf281_bb0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2307\/2530454","article-title":"Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis","volume":"38","author":"Anderson","year":"1982","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/dkf281_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/dkf281_bb0100","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1023\/A:1008348904180","article-title":"Advanced colorectal cancer: which regimens should we recommend?","volume":"10","author":"Koehne","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/dkf281_bb0105","first-page":"372","article-title":"Treatment options for advanced colorectal cancer continue to improve","volume":"22","author":"Scheithauer","year":"1999","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/dkf281_bb0110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-200060040-00005","article-title":"Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies","volume":"60","author":"Culy","year":"2000","journal-title":"Drugs"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419637713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419637713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/10\/1583\/400337\/mdf281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:34:09Z","timestamp":1582184049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419637713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S0923753419637713"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/dkf281","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}